Novo Nordisk is Falling. A Rival Weight-Loss Drug Is on the Way.
Novo Nordisk stock was dropping on Wednesday after Roche said it had licensed a promising obesity drug in a deal that could ...
Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results
New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...
Why Novo Nordisk Stock Is Falling Today
The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss ...
Novo Nordisk Stock Slides After Obesity Drug Trial Disappoints
Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in ...
Novo Nordisk's new obesity drug trial data disappoints again
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
Novo Nordisk: CagriSema Disappoints Again
Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial
Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68 ...
Novo Nordisk Shares Drop After CagriSema Trial Data Falls Short of Expectations
CagriSema produced an average 15.7% weight reduction in overweight or obese individuals with type 2 diabetes, according to ...
Fierce Biotech2d
Novo Nordisk links CagriSema to 16% weight loss, sending stock down again
Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. | Novo Nordisk’s vision of 25%-plus weight ...
pharmaphorum2d
Novo Nordisk's CagriSema data disappoints investors again
Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline ...
Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly
Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss pharmaceutical firm signed an exclusive agreement with Zealand Pharma to produce ...